Articles tagged with Parkinsons Disease
A unique mutation in the ACMSD gene has been identified in a 74-year-old man with Parkinson's disease, which may be linked to an increased risk of neurodegeneration. This discovery could lead to a better understanding of the disease and potentially inform the development of new therapeutic strategies.
Researchers found that Parkinson's disease may be caused by maladaptive brain rewiring in the subthalamic nucleus, leading to impaired movement. The study challenges the traditional understanding of brain dysfunction in Parkinson's disease.
Researchers found that intermittent electrical stimulation improved working memory in adult non-human primates, whereas continuous deep brain stimulation impaired memory. The study suggests that increased acetylcholine levels and blood flow may contribute to the benefits of intermittent stimulation.
Researchers have identified a toxic cascade in Parkinson's disease and found that treating dopamine neurons with antioxidants early on may prevent degeneration and improve neuron function. The study also highlights the importance of studying human neurons to develop new therapies.
A team of researchers in Australia developed an automatic system to diagnose Parkinson's disease severity from drawing speed and pen pressure measurements. The system combines these metrics into a single measurement, the Composite Index of Speed and Pen-pressure score, allowing for accurate diagnosis and monitoring of treatment effects.
A study published in Neurology found that a scratch-and-sniff test may predict Parkinson's disease up to six years before diagnosis. The test showed strong links between smell and disease risk for white participants, but weaker associations for black participants. Older men with poor sense of smell were more likely to develop the disease.
A study found that older adults with poor sense of smell are more likely to develop Parkinson's disease than those who perform better on the test. The researchers also found a stronger link between poor smell and disease in men, but not in women. The test could help identify people at greater risk up to six years before diagnosis.
Researchers have developed a new diagnostic software that can detect Parkinson's disease in its earliest stages, using readily available technologies. The tool records how a person draws a spiral and analyzes the data to calculate the severity of the condition with 93% accuracy.
Researchers found that an antidepressant drug, nortriptyline, slowed the growth of abnormal proteins associated with Parkinson's disease. The study suggests a potential new approach to treating the disease, which could be simpler and more effective than current therapies.
Researchers at the University of Bergen have found that asthma medicine can halve a patient's risk of developing Parkinson's disease. The study analyzed over 100 million Norwegian prescriptions and discovered a link between asthma medicine and reduced Parkinson's risk.
A new clinical investigation is testing whether genetic screening can identify patients with a specific mutation who are the best candidates for deep brain stimulation surgery. The study aims to determine how this genetic information can inform surgical decisions and potentially improve outcomes for Parkinson's disease patients.
Researchers identified beta-2 adrenergic receptor agonists as compounds that can suppress alpha-synuclein gene expression, reducing the genetic risk factor for Parkinson's disease. The findings suggest that widely used beta-2AR agonists should be rigorously tested in PD patients.
A new pathway to target Parkinson's disease has been identified, leveraging beta2-adrenergic agonists that lower alpha-synuclein production. Studies in mice and human health records suggest a 34% reduced PD risk for patients taking salbutamol.
Researchers found a difference in gut bacteria between Parkinson's patients and healthy individuals even at an early stage of the disease. Certain microbes are associated with non-motor symptoms like depression. The study aims to better understand the microbiome's role in the disease.
Researchers review neuroinflammation as a key factor in Alzheimer's and Parkinson's diseases, highlighting four modifiable risk factors: physical inactivity, vascular disease-related conditions, obesity, and type two diabetes mellitus. Controlling these risk factors may help manage the increasing incidence of both diseases.
Researchers at Arizona State University have developed an early blood test for Alzheimer's disease that can detect the disease before symptoms appear. The test distinguishes between Alzheimer's, Parkinson's, and healthy controls by analyzing RNA transcripts in white blood cells.
The Blink Reflexometer device detects changes in blinking patterns to identify concussions and neurological disorders like Parkinson's, Huntington's, and schizophrenia. The technology aims to provide a portable, rugged, and fast aid for trainers to make objective calls about player safety.
A new study by the American Academy of Neurology found that telemedicine is as effective as traditional in-person care for people with Parkinson's disease. Virtual house calls provided convenience and comfort without compromising quality of life.
A nationwide program showed that telemedicine can deliver quality care to people with Parkinson's disease in their homes via video conferencing. The study found that virtual house calls were as effective as in-person visits, saving patients time and travel, while improving access to care for those with limited mobility.
A team of scientists at UC San Diego has found that lysosomes can travel to distant parts of neurons' dendrites and branch-like areas, playing a key role in remodeling and plasticity. This discovery may provide new insights into the development of neurodegenerative diseases.
A new study published in The Lancet suggests that a diabetes drug may have disease-modifying potential to treat Parkinson's disease, improving motor function in patients. Researchers found that people with Parkinson's who used exenatide for one year performed better in movement tests than those who injected a placebo.
Researchers developed a smartphone-based biofeedback rehabilitation system to guide patients through balance exercises, showing noticeable improvements in postural stability and reducing the risk of falls. The custom wearable belt uses vibrating actuators to provide personalized guidance, mapped in real-time on a smartphone application.
Researchers at Binghamton University have developed a new drug that demonstrates superior anti-parkinsonian efficacy over current medications. The compound, D-512, provides longer symptom relief and prolongs the time window in which benefits are shown.
Researchers found that T cells from people with PD responded to alpha-synuclein to a greater degree than those gathered from healthy controls. Four genetic variations were associated with T cell reactivity, and over half of people with PD carried at least one variant.
Researchers found that fluid changes in a specific brain area could provide a way to track Parkinson's damage, with increased free water linked to worsening symptoms and progressive degeneration of neurons.
A team of researchers has successfully manufactured microscopic versions of silkworm cocoons, which can store and protect sensitive molecular materials. The tiny capsules, made from silk nano-fibrils, have the potential to increase the stability and lifetime of antibodies used in pharmaceuticals for treating severe diseases.
A study found significant abnormalities in Parkinson's disease patients' visual systems, including optic radiations alterations and white matter concentration reductions. These changes may serve as biomarkers for early detection and monitoring of the disease.
Researchers found that patients with Parkinson's were four times more likely to have a history of melanoma than those without the disease. In contrast, people with melanoma had a fourfold higher risk of developing Parkinson's. The study suggests that common environmental or genetic factors may underlie both conditions.
Researchers found that the AEP enzyme trims alpha-synuclein into toxic pieces, similar to its effect on tau in Alzheimer's disease. This discovery offers a potential drug target for Parkinson's disease.
A clinical trial found that noninvasive brain stimulation and physical therapy alone or in combination improve some measures of walking ability in patients with Parkinson's disease. Walking speed increased by an average of 19 percent, with improvements lasting for at least eight weeks after treatment.
Scientists at Georgetown University Medical Center found that alpha-Synuclein, a protein implicated in Parkinson's disease, is released when an infection occurs in the upper GI tract, inducing an immune response. Chronic infections may overwhelm the body's capacity to clear alpha-Synuclein, leading to disease.
Researchers have discovered that correct connections between brain regions are essential for optimal relief of Parkinson's Disease symptoms using deep brain stimulation. By analyzing brain connectivity, they were able to predict the best possible outcome and optimize electrode placement.
Researchers found that autoimmunity plays a role in Parkinson's disease, where the immune system attacks the body's own tissues. The study identified alpha-synuclein protein as a trigger for immune response, raising hope for new diagnostic tests and therapies to prevent neuronal death.
A newly developed research tool may help predict a patient's risk for developing dementia in Parkinson's disease, enabling improved clinical trial design and treatment development. A computer-based risk calculator was built from data on 3,200 people with Parkinson's disease, evaluating seven known risk factors.
A new research tool may predict a patient's risk for developing dementia in Parkinson's disease, enabling the design of 'smarter' trials that require fewer participating patients. The tool was built using data from 3,200 people with PD and evaluates seven known clinical and genetic risk factors.
Duke University researchers have identified a potential new mechanism for Parkinson's disease, suggesting that misfolded alpha-synuclein protein spreads from gut endocrine cells to the brain. This finding could lead to earlier diagnosis and development of therapies targeting the protein.
Researchers analyzed data from over 50 million people and found that prior statin use was associated with a higher risk of developing Parkinson's disease. The association was more noticeable in people taking lipophilic statins, and was most robust for those using the medication for less than two-and-a-half years.
A recent study published in PLOS Medicine suggests that genetic variants associated with higher body mass index (BMI) are linked to lower risk of Parkinson disease. The researchers used a Mendelian randomization approach to examine the relationship between BMI and Parkinson disease, and found an 18% lower risk of Parkinson disease amon...
A new study found that a molecular compound called CLR01 improves balance and coordination in mice with early-stage Parkinson's disease. CLR01 reduces the amount of toxic alpha-synuclein protein in the brain, which is thought to contribute to the development of the disorder.
A large study published in Neurology found that consuming at least three servings of low-fat dairy per day is associated with a greater risk of developing Parkinson's disease compared to less than one serving. The study also found an increased risk for those drinking more than one serving of low-fat or skim milk per day.
Researchers at the University of Central Florida have developed a new screening tool for Parkinson's disease using CRISPR technology. The tool allows scientists to monitor brain protein alpha-synuclein levels, which can help identify potential treatments.
Researchers at OIST Graduate University have identified the precise toxic mechanism of alpha-synuclein, a key causative agent in Parkinson's development. The protein inhibits vesicle endocytosis, critical for neurotransmission, leading to its devastating effects on motor control and cognitive function.
Research in npj Parkinson’s Disease suggests a link between influenza virus infection and the development of Parkinson’s disease. Mice infected with H1N1 influenza were more susceptible to chemical toxins that trigger Parkinson’s symptoms, but vaccination or antiviral medications mitigated this effect.
Researchers found that abnormal proteins in Alzheimer's, Parkinson's, and Huntington's diseases cause the same type of vesicle damage, potentially leading to effective treatments for multiple neurodegenerative diseases.
Researchers have pinpointed a common protein abnormality, SOD1 fingerprint, in Parkinson's disease brains, suggesting a new target for therapies that improved ALS outcomes. The finding may lead to substantial improvements in motor function and survival time for Parkinson's patients.
Researchers identified neural circuits behind sensory deficits in Parkinson's disease by studying mice with dopamine-depleted brains. The study found that treating mice with L-DOPA restored their ability to distinguish between left and right whiskers, offering new avenues for earlier diagnosis.
A study found significant racial disparities in neurologic healthcare access and utilization in the US. Black and Hispanic individuals had lower rates of outpatient neurologist visits and more hospital emergency department visits compared to white individuals.
Researchers identified biomarkers that correlate with cognitive decline in early Parkinson's disease, including dopamine deficiency, brain atrophy, and genetic mutations. The study may improve clinical care and develop new treatments for cognitive impairments in Parkinson's disease.
Researchers identified brain scans, genetic tests, and CSF analysis as predictive biomarkers for Parkinson's disease-related cognitive decline. Biomarkers associated with dopamine deficiency, beta-amyloid protein, and single nucleotide polymorphisms were found to correlate with cognitive impairment in newly diagnosed patients.
Researchers at MIT have developed a new brain implant design that uses thin fibers to deliver drugs or electrical stimulation with less damage to the brain. The design reduces scarring, potentially allowing devices to remain in the brain for much longer.
A Mayo Clinic study found that patients with Parkinson's disease, Lewy body dementia, and related conditions died 2-6 years earlier than the general population. The study used data from 1991 to 2010 and compared 461 patients with these diseases to 452 patients in the general population.
A study published in JAMA Neurology found that patients with Parkinson disease and dementia with Lewy bodies died approximately two years earlier than the general population. The highest risk of death was seen among those with multiple system atrophy with parkinsonism, highlighting the need for tailored care and management strategies.
Researchers at Carnegie Mellon University have identified two groups of neurons that can be targeted with optogenetics to alleviate Parkinson's disease symptoms. By activating these cells, they were able to restore movement for at least four hours, significantly longer than current treatments.
A new special collection in Disease Models & Mechanisms (DMM) explores the intersection of models and mechanisms to therapies for neurodegenerative disorders. The collection includes articles on induced pluripotent stem cell models, antisense oligonucleotide therapy for spinal muscular atrophy, and more.
Researchers have discovered that doxycycline can reduce α-synuclein aggregation and improve symptoms in animal models of Parkinson's disease. This could lead to a potential treatment option for the degenerative condition.
University at Buffalo researchers have successfully reproduced Parkinson's brain oscillations in a petri dish using stem cells. This breakthrough could speed up the development of new treatments and even lead to a cure for Parkinson's disease.
A recent study found that people who had a truncal vagotomy at least five years earlier were 40% less likely to develop Parkinson's disease than those who did not have the surgery. The study suggests that the gut may play a role in the development of Parkinson's disease, which often involves gastrointestinal problems.
A research team at DGIST has discovered a candidate substance that can prevent and potentially cure Parkinson's disease by inducing the expression of the parkin protein. Cortisol, a stress hormone, promotes the production of this protein, which protects dopaminergic neurons from death.
A new study on UHT milk has found a link between protein clusters and age-related diseases like Alzheimer
A new study found that the old drug apomorphine can significantly reduce 'off' times in patients with advanced Parkinson's disease, improving their quality of life. The treatment was effective even after just one week and was well-tolerated.